Sabin Vaccine Institute Company Profile

Background

The Sabin Vaccine Institute, established in 1993 and headquartered in Washington, D.C., is a global nonprofit organization dedicated to advancing vaccine development and expanding immunization coverage worldwide. Named after Dr. Albert B. Sabin, the creator of the oral polio vaccine, the institute honors his commitment to making vaccines accessible to all individuals, particularly the most vulnerable populations. The organization's mission is to make vaccines more accessible, enable innovation, and expand immunization across the globe.

Key Strategic Focus

The Sabin Vaccine Institute focuses on several strategic areas:

• Vaccine Development and Research: Prioritizing the development of vaccines for diseases with limited commercial interest but high public health value, such as Marburg virus and Sudan ebolavirus.

• Advocacy and Education: Collaborating with global experts and organizations to enhance knowledge of infectious diseases and promote vaccine acceptance.

• Global Immunization: Empowering immunization professionals and fostering innovative thinking to advance next-generation vaccines and ensure equitable access.

• Capacity Building: Strengthening individual and institutional capabilities through targeted training and knowledge-sharing platforms.

Financials and Funding

As a nonprofit organization, the Sabin Vaccine Institute has secured funding through various grants and partnerships. Notably, in March 2020, the institute received a $10.4 million grant. In January 2023, it raised an additional $35 million in funding. These funds are utilized to support vaccine research and development, advocacy initiatives, and capacity-building programs aimed at enhancing global immunization efforts.

Pipeline Development

The institute is actively involved in the development of vaccines for several infectious diseases:

• Marburg Virus Disease and Sudan Ebolavirus Disease: Sabin has licensed the cAd3 vaccine platform from GSK and is advancing single-dose investigational vaccines for these diseases through Phase 2 clinical trials.

• Typhoid Fever: Sabin has conducted landmark studies to establish the burden of enteric fever in Southeast Asian communities, providing key evidence to support the introduction of new typhoid conjugate vaccines into routine immunization schedules.

Technological Platform and Innovation

The Sabin Vaccine Institute employs several innovative approaches:

• cAd3 Vaccine Platform: A proprietary technology licensed from GSK, utilized in the development of vaccines for Marburg virus and Sudan ebolavirus.

• Social and Behavioral Research: Conducting studies to understand factors influencing vaccine acceptance and coverage, particularly in low- and middle-income countries.

Leadership Team

The leadership team of the Sabin Vaccine Institute includes:

• Amy Finan: Chief Executive Officer, leading the institute's strategic direction and operations.

• Dr. Rebecca Martin: President of Global Immunization, overseeing global immunization programs and partnerships.

Competitor Profile

The Sabin Vaccine Institute operates in the global public health sector, focusing on vaccine development and immunization. Key competitors include:

• GAVI, the Vaccine Alliance: A public-private partnership that aims to increase access to immunization in poor countries.

• World Health Organization (WHO): A specialized agency of the United Nations responsible for international public health.

• PATH: An international nonprofit organization that drives transformative innovation to save lives and improve health, especially among women and children.

Strategic Collaborations and Partnerships

The Sabin Vaccine Institute collaborates with various organizations to enhance its impact:

• International Vaccine Institute (IVI): In 2012, Sabin partnered with IVI to combine research, development, and promotion efforts in Asia, Africa, and the Americas.

• National Institutes of Health (NIH): Collaborating on research for vaccines targeting outbreak-prone diseases.

Operational Insights

The Sabin Vaccine Institute differentiates itself through:

• Focus on Neglected Diseases: Prioritizing vaccines for diseases with limited commercial interest but high public health impact.

• Global Reach: Engaging in partnerships and programs across multiple continents to enhance immunization coverage.

Strategic Opportunities and Future Directions

The institute's strategic roadmap includes:

• Expanding Vaccine Development: Advancing research for vaccines targeting additional infectious diseases.

• Strengthening Global Partnerships: Building collaborations with governments, NGOs, and the private sector to enhance immunization efforts.

• Enhancing Vaccine Acceptance: Implementing programs to increase public trust and acceptance of vaccines worldwide.

Contact Information

• Website: www.sabin.org

• LinkedIn: Sabin Vaccine Institute